Fong Clow

12.4k total citations · 1 hit paper
30 papers, 1.2k citations indexed

About

Fong Clow is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Fong Clow has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 18 papers in Pathology and Forensic Medicine and 11 papers in Hematology. Recurrent topics in Fong Clow's work include Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Fong Clow is often cited by papers focused on Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Fong Clow collaborates with scholars based in United States, United Kingdom and Australia. Fong Clow's co-authors include Danelle F. James, Ian W. Flinn, Lori Styles, Cathy Zhou, Susan O’Brien, Carol Moreno, Fatih Demırkan, Martin Šimkovič, Jan Novák and Владимир Стругов and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Fong Clow

30 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

2018 380 citations Carol Moreno, Richard Greil et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Fong Clow

Since Specialization

Citations

This map shows the geographic impact of Fong Clow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fong Clow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fong Clow more than expected).

Fields of papers citing papers by Fong Clow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fong Clow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fong Clow. The network helps show where Fong Clow may publish in the future.

Co-authorship network of co-authors of Fong Clow

This figure shows the co-authorship network connecting the top 25 collaborators of Fong Clow. A scholar is included among the top collaborators of Fong Clow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fong Clow. Fong Clow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection 2022 ·Open Forum Infectious Diseases ·Pablo C. Okhuysen, Mayur Ramesh, Kevin W. Garey, Thomas Louie, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), José G. Montoya, Lori Styles, Fong Clow, Danelle F. James, Erik R. Dubberke, Cláudia Murta de Oliveira, Christophe Van Steenkiste	6
2	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study 2019 ·Biology of Blood and Marrow Transplantation ·Edmund K. Waller, David B. Miklos, Corey Cutler, Mukta Arora, Madan Jagasia, Iskra Pusic, Mary E.D. Flowers, Aaron C. Logan, Ryotaro Nakamura, Stephen Chang, Fong Clow, Indu Lal, Lori Styles, Samantha Jaglowski	66
3	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials 2018 ·British Journal of Haematology ·Jeffrey A. Jones, Anthony R. Mato, Steven Coutré, John C. Byrd, Richard R. Furman, Peter Hillmen, Anders Österborg, Constantine S. Tam, Stephan Stilgenbauer, William G. Wierda, Nyla A. Heerema, Karl Eckert, Fong Clow, Cathy Zhou, Alvina D. Chu, Danelle F. James, Susan O’Brien	32
4	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial breakdown → 2018 ·The Lancet Oncology ·Carol Moreno, Richard Greil, Fatih Demırkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Šimkovič, Olga Samoilova, Jan Novák, Dina Ben‐Yehuda, Владимир Стругов, Devinder Gill, John G. Gribben, Emily Hsu, Chih‐Jian Lih, Cathy Zhou, Fong Clow, Danelle F. James, Lori Styles, Ian W. Flinn	380
5	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results 2018 ·British Journal of Haematology ·Paul G. Richardson, William Bensinger, Carol Ann Huff, Caitlin Costello, Nikoletta Lendvai, Jesús G. Berdeja, Larry D. Anderson, David S. Siegel, Daniel Lebovic, Sundar Jagannath, Jacob P. Laubach, Keith Stockerl‐Goldstein, Long Kwei, Fong Clow, Laurence Elias, Zeena Salman, Thorsten Graef, Elizabeth Bilotti, Ravi Vij	30
6	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE 2018 ·Blood ·Carol Moreno, Richard Greil, Fatih Demırkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Šimkovič, Olga Samoilova, Jan Novák, Dina Ben‐Yehuda, Владимир Стругов, Devinder Gill, John G. Gribben, Emily Hsu, Cathy Zhou, Fong Clow, Danelle F. James, Lori Styles, Ian W. Flinn	7
7	Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis 2017 ·Blood ·Simon Rule, Martin Dreyling, André Goy, Georg Heß, Rebecca Auer, Brad S. Kahl, José‐Ángel Hernández‐Rivas, Anil Londhe, Fong Clow, Sanjay Deshpande, Lori Parisi, Michael Wang	4
8	Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies 2016 ·Haematologica ·Simon Rule, Martin Dreyling, Gregory P. Hess, Rebecca Auer, Brad S. Kahl, (unknown), (unknown), Fong Clow, Judith D. Goldberg, Darrin M. Beaupre, Jessica Vermeulen, Mark Wildgust, (unknown)	2
9	Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials 2015 ·Blood ·Peter Hillmen, Graeme Fraser, Jeffrey A. Jones, Simon Rule, Susan O’Brien, (unknown), Ulrich Jaeger, Sebastian Grosicki, Florence Cymbalista, Steven Sun, Joi Ninomoto, Michelle Mahler, Mei Cheng, Joris Diels, Fong Clow, Mariya Salman, Danelle F. James, Angela Howes, Asher Chanan‐Khan	20
10	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia 2015 ·Blood ·Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, Ian W. Flinn, Jan A. Burger, (unknown), Fong Clow, Danelle F. James, Thorsten Graef, Jonathan W. Friedberg, R. Kanti, Susan O’Brien	91
11	Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib 2014 ·Annals of Hematology ·David Smith, Leanne Goldstein, Mei Cheng, Danelle F. James, Lori Kunkel, Maria Fardis, Ahmed Hamdy, Raquel Izumi, Joseph J. Buggy, Fong Clow	8
12	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results 2014 ·Blood ·Ravi Vij, Carol Ann Huff, William Bensinger, David S. Siegel, Sundar Jagannath, Jesús G. Berdeja, Nikoletta Lendvai, Daniel Lebovic, Larry D. Anderson, Caitlin Costello, Keith Stockerl‐Goldstein, Jacob P. Laubach, Laurence Elias, Fong Clow, Maria Fardis, Thorsten Graef, Elizabeth Bilotti, Paul G. Richardson	9
13	Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. 2014 ·Journal of Clinical Oncology ·John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jäger, Stephen Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen	7
14	Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study 2013 ·Blood ·Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, Ian W. Flinn, Jan A. Burger, Zeena Salman, Fong Clow, Danelle F. James, Thorsten Graef, Jonathan W. Friedberg, R. Kanti, Susan O’Brien	40
15	The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study 2013 ·Blood ·Susan O’Brien, Richard R. Furman, Nathan Fowler, Steven Coutré, Jeff P. Sharman, Kristie A. Blum, Jan A. Burger, Jeffrey A. Jones, William G. Wierda, (unknown), Ian W. Flinn, Ranjana H. Advani, Kathryn S. Kolibaba, (unknown), Fong Clow, Danelle F. James, Alvina D. Chu, John C. Byrd	8
16	Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy. 2013 ·Journal of Clinical Oncology ·David Loury, Juthamas Sukbuntherng, Fong Clow, Danelle F. James, Lori Kunkel	6
17	Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA). 2013 ·Journal of Clinical Oncology ·Jan A. Burger, Paolo Ghia, Aaron Polliack, Constantine S. Tam, (unknown), Fong Clow, Silvija Kraljevic, Danelle F. James, Thomas J. Kipps	8
18	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study 2012 ·Blood ·John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Barbara Grant, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, (unknown), Fong Clow, Lori Kunkel, Danelle F. James, Susan O’Brien	44
19	Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators 2007 ·Journal of Clinical Oncology ·Tomasz M. Beer, Christopher W. Ryan, Peter Venner, Daniel P. Petrylak, Gurkamal Chatta, Joseph D. Ruether, Charles H. Redfern, Louis Fehrenbacher, Mansoor N. Saleh, David Waterhouse, Michael A. Carducci, Daniel Vicario, Robert Dreicer, Celestia S. Higano, Frederick R. Ahmann, Kim N., W. David Henner, (unknown), Fong Clow	235
20	Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT 2006 ·Journal of Clinical Oncology ·Tomasz M. Beer, Chris Ryan, Peter Venner, Daniel P. Petrylak, (unknown), Joseph D. Ruether, (unknown), (unknown), Fong Clow	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact